Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial.

TY - JOUR

T1 - Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial.

AU - Schuchardt, J P

AU - Neubronner, J

AU - Kressel, G

AU - Merkel, Martin

AU - von Schacky, C

AU - Hahn, A

PY - 2011

Y1 - 2011

N2 - Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01g EPA+0.67g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.

AB - Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01g EPA+0.67g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Patient Compliance

KW - Double-Blind Method

KW - Analysis of Variance

KW - Biological Availability

KW - Docosahexaenoic Acids/pharmacokinetics/therapeutic use

KW - Dyslipidemias/drug therapy

KW - Eicosapentaenoic Acid/pharmacokinetics/therapeutic use

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Hypolipidemic Agents/therapeutic use

KW - Triglycerides/blood

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Patient Compliance

KW - Double-Blind Method

KW - Analysis of Variance

KW - Biological Availability

KW - Docosahexaenoic Acids/pharmacokinetics/therapeutic use

KW - Dyslipidemias/drug therapy

KW - Eicosapentaenoic Acid/pharmacokinetics/therapeutic use

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Hypolipidemic Agents/therapeutic use

KW - Triglycerides/blood

M3 - SCORING: Journal article

VL - 85

SP - 381

EP - 386

JO - PROSTAG LEUKOTR ESS

JF - PROSTAG LEUKOTR ESS

SN - 0952-3278

IS - 6

M1 - 6

ER -